Findings from the IMPLEMENT sub-analysis investigating sufferers with metastatic castration-sensitive prostate most cancers present variations in remedy intensification adoption between tutorial and nonacademic physicians, in line with Dr. Neeraj Agarwal.
On the 2025 ASCO Genitourinary Cancers Symposium, Agarwal sat down for an interview with CURE® to debate the trial. Within the two-phase examine, investigators revealed that, of the recognized limitations and facilitators to remedy intensification, nonacademic physicians and low-intensity prescribers extra continuously reported obstacles reminiscent of information gaps and considerations about unwanted effects, whereas tutorial physicians and high-intensity prescribers cited medical assist and survival advantages as key motivators.
Agarwal is a medical oncologist, a professor of medication and the Presidential Endowed Chair of Most cancers Analysis on the Huntsman Most cancers Institute, College of Utah, in addition to director of the Genitourinary Oncology Program and the Heart of Investigational Therapeutics on the Huntsman Most cancers Institute in Salt Lake Metropolis.
Transcript:
There’s a clear distinction between the limitations confronted by excessive intensifiers versus low intensifiers. An method to unravel this drawback goes to be physician-specific or practice-specific. From a affected person’s perspective, I’d urge our sufferers to speak to their physicians in regards to the totally different remedy choices which can be found for them. Until they ask, they weren’t going to make them suppose so.
If, say, there’s a low intensifier doctor who will not be utilizing this remedy, they usually’re nonetheless utilizing, for instance, ADT plus bicolutomide, which is a first-generation anti-androgen, and they’re completely happy utilizing that drug as a substitute of a second era ARPI with or with out chemotherapy, if sufferers ask this query to their docs, ‘What are the remedy choices out there for me?’ and ‘What has been developed within the final 5 or 6 years?’ that will make these busy physicians and clinicians take into consideration these choices and return and examine them, or at the least get to find out about these choices.
When the affected person comes again for the second go to, then they’re extra prepared to debate these questions with them, with the newest knowledge, if you’ll. That is how I believe it can affect the sufferers.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
